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The human Metapneumovirus (HMPV), a new member of the
Paramyxoviridae family, has been recently associated with res-
piratory tract infections in young children. We report the case of
a young, immunocompromised child who had severe lower res-
piratory tract infections during two consecutive winter seasons
caused by genetically distinct HMPV strains.
 variety of viruses—such as the influenza viruses A and
B, the Human respiratory syncytial virus (HRSV), the
parainfluenza viruses, and the adenoviruses—cause seasonal
respiratory tract infections in young children. Symptoms range
from influenzalike illnesses to lower respiratory tract syn-
dromes, such as bronchiolitis, croup, and pneumonitis (1–4).
These viruses may also cause severe respiratory infections in
immunocompromised patients (1,4). However, the cause of
many cases of bronchiolitis and pneumonitis remains
unknown despite the extensive use of sensitive diagnostic
techniques. 
The human metapneumovirus (HMPV) has been recently
classified as a new member of the Paramyxoviridae family
based on nucleic acid sequence, gene organization, and elec-
tron microscopy findings (5–7). This virus has been reported
to cause respiratory tract infections in children <5 years of age
from the Netherlands (5), as well as in elderly patients from
North America (7). We describe a case of recurrent HMPV
respiratory tract infections, associated with genetically distinct
viral strains, in an immunocompromised child.
Case Report
A 7-month-old girl, who had acute lymphoblastic leuke-
mia with meningeal involvement (treated with intravenous
vincristine and doxorubicin, as well as intrathecal methotrex-
ate), was brought to the hospital on March 23, 1998, for recent
onset of nasal congestion and nonproductive cough. Her medi-
cal history showed that she had recent contact with family
members who had a common cold. On initial physical exami-
nation, her temperature was 38.9°C with a respiratory rate of
40 per min, with no rales at lung auscultation. Initial labora-
tory tests showed a leukocyte count of 1,800 X 109 cells/L
with 25% neutrophils and 3% band forms. The child was hos-
pitalized and treated empirically with intravenous ceftazidime.
Urine and blood cultures were negative for bacterial patho-
gens. The patient rapidly improved and was discharged from
the hospital on day 3 after admission; no antibiotics were
given, and the presumptive diagnosis was viral upper respira-
tory tract infection. The next day, the patient was brought to
the same hospital for an exacerbation of coughing and sneez-
ing. On physical examination, she had a temperature of
38.5°C, with bilateral wheezing at lung auscultation. The res-
piratory rate was 36 per min, and a clear nasal discharge was
noted. The leukocyte count was 1,600 x 109 cells/L, with 33%
neutrophils and 0% band forms. Blood was drawn for cultures,
and a nasopharyngeal aspirate (NPA) sample was obtained for
HRSV antigenic testing (Test Pack, Abbott Laboratories,
Abbott Park, IL) and viral culture on Madin Darby Kidney
cells (MDKC), tertiary monkey kidney cells (LLC-MK2),
Hep-2, human foreskin fibroblast, Vero, Mink lung, human
lung adenocarcinoma (A-549), human rhabdomyosarcoma
(RD), transformed human kidney 293, and human colon ade-
nocarcinoma (HT-29) cells. The patient was again treated
empirically with intravenous ceftazidime. Three days after
admission her condition had improved, and she was dis-
charged from the hospital. The final diagnosis was bronchioli-
tis, and antibiotics were not given. Bacterial blood cultures and
the rapid antigenic test for HRSV were negative. However,
after 17 days of incubation, the viral culture from the NPA
showed a nonhemagglutinating virus (isolate 1) growing in
LLC-MK2 cells. Immunofluorescence assays with antibodies
against common respiratory pathogens (influenza viruses A
and B, HRSV, adenoviruses, and parainfluenza viruses 1–4)
were all negative. 
The next year, on January 18, 1999, during a scheduled
medical appointment for administration of intravenous
(daunorubicin and vincristine) and intrathecal (methotrexate,
cytarabine, and hydroxyurea) chemotherapy in addition to oral
dexamethasone, the now 17-month-old girl again had nasal
congestion and nonproductive cough. Her father mentioned
that he had an upper respiratory tract infection 2 weeks earlier.
An NPA sample was obtained for viral culture and HRSV anti-
genic detection. The patient did not appear ill and was allowed
to go home the same day after chemotherapy. The HRSV anti-
genic test came back negative, but the viral culture showed an
unidentified cytopathic effect only apparent in LLC-MK2 cells
after 14 days of incubation (isolate 2). Immunofluorescence
assays were again negative for all common respiratory viruses.
The patient received another course of intravenous chemother-
apy (daunorubicin and vincristine) on January 25 at the out-
patient clinic, and her upper respiratory tract symptoms were
then treated with an oral antibiotic (axetil cefuroxime).
Five days later, on January 30, 1999, the child was admit-
ted to the hospital with a fever (39.9°C), persistent dry cough,
and clear nasal discharge while on oral antibiotic. On physical
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examination, her respiratory rate was 28 per min with fine
bilateral crackles at lung auscultation. An otoscopic exam
showed bilateral otitis. The leukocyte count showed neutro-
penia (0.400 x 109 cells/L), and ceftazidime plus vancomycin
were initiated. The blood cultures taken on the first day of hos-
pitalization indicated a coagulase-negative staphylococcus (1
of 2 bottles were positive). On the fourth day of hospitaliza-
tion, the patient’s clinical condition deteriorated with desatura-
tion (pO2, 0.88) and tachypnea (respiratory rate, 60–70 per
min). A chest x-ray showed bilateral infiltrates compatible
with pneumonitis. The next day, an NPA sample was obtained
for a viral culture and direct immunofluorescent assays against
typical respiratory viruses. The results were negative. Intrave-
nous erythromycin was administered for empirical coverage of
atypical pathogens. On day 10 of hospitalization, the patient
was transferred to the pediatric intensive-care unit and was
intubated. A bronchoscopy was performed, and a bronchoalve-
olar lavage (BAL) sample was obtained for cultures of fungal,
mycobacterial, viral, and bacterial pathogens, as well as for
specific staining procedures for Pneumocystis carinii, fungi,
bacteria, and mycobacteria. At that point, ceftazidime was
replaced by trimethoprim/sulfamethoxazole, and an amphot-
ericin B lipidic complex formulation (Abelcet, Liposome,
Canada) was added. All cultures and specific staining proce-
dures performed with the BAL sample were negative. Direct
immunofluorescence assays on the BAL sample also were
negative for influenza A and B, parainfluenza 1–4, and HRSV.
On day 13 of hospitalization, the patient’s respiratory signs
deteriorated markedly, with bilateral pulmonary infiltrates
compatible with acute respiratory distress syndrome. Four
days later, because of free air in the pericardium and perito-
neum (the patient was on high ventilatory pressure), drainage
tubes were placed, resulting in a temporary improvement of
pulmonary gas exchange. New blood cultures drawn on day 27
were negative. The next day, shock developed, and vasopres-
sive drugs were started. Because of her irreversible condition,
all treatment was stopped on day 30, and the patient died
shortly thereafter. No autopsy was performed.
Two years after the child’s death, reverse transcription-
polymerase chain reaction assays for HMPV with infected
LLC-MK2 cell culture supernatants of the two unidentified
isolates were performed and found to be positive. On the basis
of partial published sequences, a set of primers was designed
for amplification of the F gene of HMPV (5,7). The forward
primer sequence was 5´-ATGTCTTGGAAAGTGGTG-3´, and
the reverse primer sequence was 5´-TCTTCTTACCATTG-
CAC-3´. Amplified products were sequenced by an automated
DNA sequencer (ABI 377A [Perkin-Elmer Applied Biosys-
tems, Foster City, CA]) and the 759-bp nucleotide sequences
of the two viral isolates from consecutive seasons were aligned
with the Clustal W software (8). The two viral isolates differed
by 114 nt in the F gene sequence, which resulted in a change of
10 amino acids (Figure).
Conclusions
We describe the case of a young immunocompromised
child who had respiratory tract infections during two consecu-
tive seasons, probably due to HMPV, a newly discovered
paramyxovirus. On the basis of sequence analysis of the viral
F gene, we found that the child was infected by two geneti-
cally distinct HMPV strains. 
In the first clinical episode (occurring at the age of 7
months), the initial symptoms resembled a common cold and
progressed to bronchiolitis, followed by a complete resolution
of symptoms within a few days. HMPV was the only organism
isolated in culture from an NPA sample, and the HRSV rapid
antigenic test was negative. Ten months later, the child had a
second respiratory tract infection, again with common cold
symptoms. HMPV was again the sole pathogen isolated in an
NPA sample. In the next weeks, however, the patient’s clinical
condition deteriorated, with development of bilateral pneu-
monitis and respiratory failure and ultimately death. The BAL
sample obtained showed no bacterial, viral, or fungal patho-
gens by culture, antigenic testing, or special staining proce-
dures. The exact cause of respiratory failure in this
immunocompromised child remains uncertain, because
autopsy was not performed. An opportunistic infection or a
neoplastic infiltrate was the most probable cause. HMPV
could have led to the acute respiratory distress syndrome in
this immunocompromised patient. We suggest that the initial
upper respiratory tract infection may have progressed to pneu-
monitis after the patient received intensive chemotherapy. The
fact that HMPV was not recovered in the last BAL sample
does not rule out such viral infection since paramyxoviruses
are very labile (1), and the culture may not have been incu-
bated long enough for a cytopathic effect to be observed.
Figure. Comparison of the partial amino acid sequences of Human
Metapneumovirus (HMPV) isolates 1 (recovered in 1998) and 2 (recov-
ered in 1999) for the fusion protein (residues 1 to 253). The sequences
were aligned with the reference sequence from the Netherlands (Gen-
Bank accession no. AF371337). Asterisks denote identical residues;
the shaded boxes highlight different amino acids between the two
HMPV isolates from this study.DISPATCHES
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The two HMPV isolates from this study had many differ-
ences at the nucleotide level (similarity 85.0%) but much less
at the amino acid level (similarity 96.0%) in the gene coding
for the fusion (F) protein. Isolate 2, recovered in 1999, had
greater amino acid similarity with the prototype sequence from
the Netherlands (5) compared with isolate 1 (98.0% vs. 96.0%
similarity). Furthermore, the two strains seem to belong to the
two different HMPV lineages previously reported by Dutch
and North American groups (5,7). We suggest that many
HMPV strains may cocirculate in a specific population, and
such viral diversity, coupled with waning immunity, as found
in elderly and immunocompromised patients, may lead to mul-
tiple reinfections similar to HRSV (2,9–12).
Future studies are needed to evaluate the full clinical spec-
trum associated with HMPV infection, the groups at risk for
severe complications, and the potential therapeutic options.
Our data suggest that HMPV should be added to the list of
pathogens associated with severe respiratory tract infections in
immunocompromised patients.
Dr. Pelletier is a postdoctoral fellow in infectious diseases at
Laval University. His research interests include the molecular detec-
tion and epidemiology of respiratory viruses.
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